Rupa Health acquired by Fullscript
Context
The acquisition of Rupa Health by Fullscript executes a strategic consolidation within the digital healthcare and diagnostic testing sectors. Announced in October 2024, this corporate transaction orchestrates the complete integration of a specialized laboratory logistics portal into a broader whole person care ecosystem. By formally absorbing the acquired technology, the Canadian buyer captures a highly complementary digital asset that directly bridges the operational gap between diagnostic testing and therapeutic supplementation. The structural integration merges an extensive external catalog of specialty diagnostic tools directly with the buyer's established treatment planning software, creating a unified clinical interface capable of gathering, analyzing, and actioning patient data seamlessly. The strategic rationale guiding the acquiring executive board explicitly focuses on establishing the preeminent digital site where diverse healthcare practitioners can manage both their laboratory ordering workflows and therapeutic dispensing from a single centralized dashboard. This combined software architecture eliminates the need for medical clinics to utilize disparate systems for diagnostics, results management, and physical interventions. The newly consolidated entity aims to empower medical providers to deliver highly personalized, evidence-based care by improving immediate access to critical diagnostic insights, decision-support tools, and continuing medical education resources. Throughout the post-transaction integration phase, the acquired academic and multimedia modules will strictly enhance the overarching value proposition offered to the acquirer's established network of medical professionals. This alignment internalizes the required data infrastructure to practice root-cause medicine at a massive scale, optimizing health outcomes for patient populations by streamlining administrative friction and standardizing patient communication. Ultimately, the definitive agreement structurally transforms the buyer into an end-to-end medical care ecosystem capable of supporting comprehensive chronic disease management and preventive health protocols across diverse care specialties and complex clinical conditions.
Rupa Health, which reported an EBITDA margin of in 2024, is valued in this transaction at an EV/EBITDA multiple of , a level to compare with the average currently observed in the Healthcare & Pharma sector (14.5x).
-> Deep-dive in Healthcare & Pharma market trends
Target
Launched in 2020 by co-founders Tara Viswanathan and Rosa Hamalainen, Rupa Health operates as a specialized digital health platform designed to modernize the logistics of laboratory testing. The healthcare technology company manages a comprehensive diagnostic infrastructure that allows medical practitioners to order, track, and manage more than 3,000 distinct specialty lab tests through a single unified interface. By integrating test ordering workflows, results management, and direct patient communication protocols, the enterprise serves an active network encompassing tens of thousands of clinics across the United States. Furthermore, the organization actively supports half a million patients and practitioners every month by centralizing critical diagnostic insights. Beyond its core laboratory logistics software, the entity directs a dedicated educational division operating under the name Rupa University. Through this specialized academic arm, the company has formally trained tens of thousands of healthcare professionals via live classes and educational bootcamps focused on personalized, root-cause medical practices. The corporate ecosystem also produces specialized multimedia resources, explicitly including the Rupa Magazine and the Root Cause Medicine Podcast, to further distribute clinical education.
Ent. Value
Equity Value
Multiples
EV / Revenue
EV / EBITDA
EV / EBIT
Historical Financials (EUR)
Similar deals in Healthcare Services
| Date | Acquirer | Target | Country | Sector |
|---|---|---|---|---|
| 04/2025 | TRANSCARENT | ACCOLADE | UNITED STATES | Health Tech |
| 04/2025 | KERSIA | NEOGEN (ANIMAL BIOSECURITY DIVISION) | UNITED STATES | Sterilization & Hygiene |
| 07/2024 | ARDIAN | MASCO GROUP | ITALY | Healthcare Services |
| 06/2024 | PERMIRA | PHARMACORD | UNITED STATES | Health Tech |
| 05/2024 | 21 INVEST / OAKLEY CAPITAL INVESTMENTS | PRODUCT LIFE | FRANCE | Healthcare Services |
| 10/2023 | MOTION EQUITY PARTNERS | BANOOK | FRANCE | CRO / Clinical Trials |
| 09/2023 | PERMIRA | ERGOMED | UNITED KINGDOM | CRO / Clinical Trials |
| 09/2023 | CERBA HEALTHCARE | CIRION BIOPHARMA RESEARCH | CANADA | CRO / Clinical Trials |
| 06/2023 | SUPERNOVA INVEST / HEAL CAPITAL | GLEAMER | FRANCE | Health Tech |
| 06/2022 | ASTORG | OPEN HEALTH | UNITED STATES | Healthcare Services |
REFERENCES
Note: This page provides detailed data on a private equity M&A transaction. Detailed and exact financial metrics for the acquisition of Rupa Health by Fullscript are reserved for mynth community members. Register for free to unlock full data.
Authors: This transaction was contributed by a verified mynth contributor and cross-checked against available transaction documents and official company communications.
Press release: view release
Target: rupa health
Acquirer: fullscript